

20 February 2025

ASX Announcement

Webinar on Firebrick Half-Year Results and 2025 Plans

Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company) is pleased to announce that there will be an investor webinar on Tuesday, 25 February 2025 at 12pm (AEDT) / 9am (AWST).

Executive Chairman and Co-Founder, Dr Peter Molloy, will be joined by Tim Sylvester from The Market Link to discuss the Company's Half Year results, its recent launch of Nasodine Nasal Spray into Fiji and South Pacific, and the Company's plans for the remainder of 2025.

The webinar will provide an important opportunity for shareholders and potential investors to receive an update on the Company's future plans and activities, and to ask questions via a Q&A segment following the discussion.

Investors are encouraged to attend and to register for the webinar using the following link:

https://us02web.zoom.us/webinar/register/WN_kMH2Lf3QXKgrhISGEOhEq#/registration

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is a pharmaceutical innovator developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The Company has developed and is now commercialising Nasodine® Nasal Spray (0.5% PVP-I) and has several other products in development. Firebrick recently introduced Nasodine in the United States, Singapore and Fiji and South Pacific, with an agreement in place to also launch Nasodine in the Philippines.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com